Studio clinico 2026-525170-19-00 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Studio clinico 2026-525170-19-00 (fase II) risulta «autorizzato» su CTIS (EU Clinical Trials Information System).

Patologia: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · Interventi registrati: Entyvio 300 mg powder for concentrate for solution for infusion, BNT327 20 mg ml, PACLITAXEL, BNT327 50 mg ml, CARBOPLATIN, INFLIXIMAB, CISPLATIN, PEMETREXED, Anti-CCR8 NF mAb · Date registrate (fonte): 2026-09-07, 2026-09-10.

Fonte: https://euclinicaltrials.eu/ctis-public/view/2026-525170-19-00